NEW YORK, October 6, 2017 /PRNewswire/ --
If you want a Stock Review on VAR, SENS, XTNT, or NVCR then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. This morning, DailyStockTracker.com presents for review: Varian Medical Systems Inc. (NYSE: VAR), Senseonics Holdings Inc. (NYSE AMER: SENS), Xtant Medical Holdings Inc. (NYSE AMER: XTNT), and NovoCure Ltd (NASDAQ: NVCR). Companies in the Medical Appliances and Equipment space are engaged in the manufacture of medical instruments such as dental and surgical appliances. They tend to offer below-average dividend yields when compared to the wider market. Learn more about these stocks by signing up for their free reports on DailyStockTracker.com at: http://dailystocktracker.com/register/
Varian Medical Systems
On Thursday, shares in Palo Alto, California headquartered Varian Medical Systems Inc. recorded a trading volume of 819,500 shares, which was above their three months average volume of 755,450 shares. The stock ended the session 0.52% higher at $102.49. The Company's shares have gained 28.91% on an YTD basis. The stock is trading 0.51% above its 50-day moving average and 9.37% above its 200-day moving average. Moreover, shares of Varian Medical Systems, which designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide, have a Relative Strength Index (RSI) of 49.76.
On September 07th, 2017, research firm BTIG Research downgraded the Company's stock rating from 'Buy' to 'Neutral'.
On September 21st, 2017, Varian Medical Systems announced that a patient with head and neck cancer at Penn Medicine became the first person in the world to be treated on the Company's Halcyon™ system, its new platform for cancer treatment. Halcyon is well suited to handle the majority of cancer patients, offering advanced treatments for prostate, breast, head and neck, and many other forms of cancer. The free research report on VAR is available at: http://dailystocktracker.com/registration/?symbol=VAR
Germantown, Maryland headquartered Senseonics Holdings Inc.'s stock closed the day 3.34% lower at $3.18 with a total trading volume of 405,061 shares. The Company's shares have advanced 2.25% in the past month, 67.37% in the previous three months, and 19.10% since the start of this year. The stock is trading 13.05% and 41.79% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Senseonics, which designs, develops, and commercializes glucose monitoring systems for people with diabetes primarily in Europe, have an RSI of 56.02.
On September 12th, 2017, Senseonics Holdings announced that it has received CE Mark approval for the Eversense® XL Continuous Glucose Monitoring (CGM) System. The Eversense XL System includes an extended life implanted glucose sensor lasting up to 180 days, a removable discreet smart transmitter, and a mobile app for display of real-time glucose readings. The Eversense XL System provides the world's longest-lasting sensor, compared to the frequent weekly sensor insertions required by other CGM systems. The complimentary report on SENS can be downloaded at: http://dailystocktracker.com/registration/?symbol=SENS
Xtant Medical Holdings
Shares in Belgrade, Montana headquartered Xtant Medical Holdings Inc. recorded a trading volume of 326,712 shares. The stock ended yesterday's trading session 2.54% higher at $0.74. The Company's shares have advanced 19.37% in the previous three months and 34.56% on an YTD basis. The stock is trading above its 200-day moving average by 22.29%. Furthermore, shares of Xtant Medical have an RSI of 45.48.
On September 12th, 2017, Xtant Medical announced that the US Food and Drug Administration has cleared product line extensions for the Irix-A interbody spacer. The clearance provides for the addition of three additional size configurations for an expanded market opportunity, and importantly, for use with allograft. Visit us today and download our complete research report on XTNT for free at: http://dailystocktracker.com/registration/?symbol=XTNT
Saint Helier, the Channel Islands-based NovoCure Ltd's stock finished Thursday's session 4.25% lower at $19.15. A total volume of 3.14 million shares was traded, which was above their three months average volume of 963,940 shares. The Company's shares have advanced 6.09% over the previous three months and 143.95% since the start of this year. The stock is trading above its 200-day moving average by 45.55%. Additionally, shares of NovoCure have an RSI of 41.22.
On October 02nd, 2017, NovoCure announced that it will report financial results for Q3 2017 on October 26th, 2017, before the US financial markets open. Management will host a conference call and webcast at 8:00 a.m. EDT that same day to discuss the financial results for the three and nine months ended September 30th, 2017. The webcast can be accessed live under the Investor Relations page of the Company's website. Get free access to your technical report on NVCR at: http://dailystocktracker.com/registration/?symbol=NVCR
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.